Join our C2N Diagnostics team at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) in San Francisco November 29 – December 2

Plenary and Late Breaking Oral Sessions and Posters

Multiple conference presentations and posters will offer exciting new insights relating to C2N’s PrecivityAD® blood test, p-tau MAA™, and other unique biomarkers. Clinical and analytical data will be shared in six session presentations and four scientific posters outlined below. On December 2nd, C2N CEO Dr. Joel B. Braunstein will share new data in a late-breaking oral presentation on clinical diagnostic usefulness of the PrecivityAD® test and its impact on medical decision making among practicing neurologists.

Tuesday, November 29

10:15 a.m. CTAD EU/US Task Force on Blood Biomarkers Point of view from assay industry Joel B. Braunstein, C2N Diagnostics, St. Louis, MO (United States)

Wednesday, November 30

9:20 a.m. CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials Oral Presentations 1: Relationship between blood plasma and CSF measures of Aβ 42/40, tau, and NfL species for tracking drug effects in clinical trials of Alzheimer’s disease Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (United States) 3: Implementation of plasma biomarkers into clinical practice and trials Oskar Hansson, Lund University, Lund (Sweden)   10:30 a.m. Late Breaker #1 – Tau PET associated with plasma p-tau217 and cognitive testing in preclinical AD: Screening data from the AHEAD Study A3 and A45 Trials Keith Johnson, Massachusetts General Hospital, Boston, MA (United States)   10:45 a.m. Late Breaker #2 – Plasma levels of Abeta42/40 and p-tau217 ratios increase accuracy of amyloid PET prediction in preclinical AD.  Robert Rissman, UC San Diego, La Jolla, CA (United States)   3:15 p.m. Late Breaker #4 – CSF MTBR-tau243 is a non-amyloid specific biomarker of neurofibrillary tangles of Alzheimer’s disease. Kanta Horie, Washington University School of Medicine, St. Louis, MO (United States)

Friday, December 2

9:20 a.m. Late Breaker #12 – Use of a Blood-Based Biomarker Test Impacts Clinical Decision Making Among Neurologists Evaluating Patients with Symptoms of Cognitive Impairment. Joel B. Braunstein, C2N Diagnostics, St. Louis, MO (United States)

CTAD Posters Featuring Data on the PrecivityAD® Test

Theme – Clinical Trials: Methodology Tuesday, November 29 at 4:00 p.m. to Wednesday, November 30 at 6:00 p.m. LP09 The AlzMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer's Disease Trials Sarah Walter, Alzheimer’s Therapeutic Research Institute, USC – San Diego, CA (United States)

Theme – Clinical Trials: Biomarkers including plasma Thursday, December 1 at 8:00 a.m.- 6:00 p.m. P109 Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer’s Disease Charisse N. Winston, UC San Diego, La Jolla, CA (United States)   P118 Recruitment of amyloid positive individuals and early Alzheimer’s patients in a primary care setting – results from the BioFINDER Primary Care study Sebastian Palmqvist, Lund University, Malmö (Sweden) P121 Use of the PrecivityAD® blood test in regular clinical practice: Preliminary observations from a dementia clinic Jonathan Drake, Rhode Island Hospital, Providence, RI (United States)

Congratulations to Drs. Reisa Sperling and Keith Johnson who will receive Lifetime Achievement Awards in Alzheimer’s Disease Therapeutic Research at the conference.

Meet with us!

To schedule a meeting with the C2N Team at CTAD, please email: research@c2n.com We look forward to seeing you in San Francisco!

Follow us:

‌ ‌ ‌

About C₂N Diagnostics, LLC C₂N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C₂N strives to provide exceptional laboratory services and products in the field of brain health. C₂N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.

For the latest news and updates, please visit https://precivityad.com.